222 related articles for article (PubMed ID: 34247626)
21. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
[TBL] [Abstract][Full Text] [Related]
22. DNA damage repair deficiency as a predictive biomarker for FOLFIRINOX efficacy in metastatic pancreatic cancer.
Palacio S; McMurry HS; Ali R; Donenberg T; Silva-Smith R; Wideroff G; Sussman DA; Rocha Lima CMS; Hosein PJ
J Gastrointest Oncol; 2019 Dec; 10(6):1133-1139. PubMed ID: 31949930
[TBL] [Abstract][Full Text] [Related]
23. Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants.
Macchini M; Centonze F; Peretti U; Orsi G; Militello AM; Valente MM; Cascinu S; Reni M
Cancer Treat Rev; 2021 Nov; 100():102262. PubMed ID: 34418781
[TBL] [Abstract][Full Text] [Related]
24. Targeting Defects in the Cellular DNA Damage Response for the Treatment of Pancreatic Ductal Adenocarcinoma.
Schmitt A; Feldmann G; Zander T; Reinhardt HC
Oncol Res Treat; 2018; 41(10):619-625. PubMed ID: 30286473
[TBL] [Abstract][Full Text] [Related]
25. High somatic mutations in circulating tumor DNA predict response of metastatic pancreatic ductal adenocarcinoma to first-line nab-paclitaxel plus S-1: prospective study.
Huang L; Lv Y; Guan S; Yan H; Han L; Wang Z; Han Q; Dai G; Shi Y
J Transl Med; 2024 Feb; 22(1):184. PubMed ID: 38378604
[TBL] [Abstract][Full Text] [Related]
26. The genetic landscape of pancreatic head ductal adenocarcinoma in China and prognosis stratification.
Yang Y; Ding Y; Gong Y; Zhao S; Li M; Li X; Song G; Zhai B; Liu J; Shao Y; Zhu L; Pang J; Ma Y; Ou Q; Wu X; Zhang Z
BMC Cancer; 2022 Feb; 22(1):186. PubMed ID: 35180847
[TBL] [Abstract][Full Text] [Related]
27. Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer.
Malgerud L; Lindberg J; Wirta V; Gustafsson-Liljefors M; Karimi M; Moro CF; Stecker K; Picker A; Huelsewig C; Stein M; Bohnert R; Del Chiaro M; Haas SL; Heuchel RL; Permert J; Maeurer MJ; Brock S; Verbeke CS; Engstrand L; Jackson DB; Grönberg H; Löhr JM
Mol Oncol; 2017 Oct; 11(10):1413-1429. PubMed ID: 28675654
[TBL] [Abstract][Full Text] [Related]
28. Outcomes in Patients With Pancreatic Adenocarcinoma With Genetic Mutations in DNA Damage Response Pathways: Results From the Know Your Tumor Program.
Pishvaian MJ; Blais EM; Brody JR; Rahib L; Lyons E; De Arbeloa P; Hendifar A; Mikhail S; Chung V; Sohal DPS; Leslie S; Mason K; Tibbets L; Madhavan S; Matrisian LM; Petricoin E
JCO Precis Oncol; 2019 Dec; 3():1-10. PubMed ID: 35100730
[TBL] [Abstract][Full Text] [Related]
29. The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma.
Moffat GT; O'Reilly EM
Clin Adv Hematol Oncol; 2020 Mar; 18(3):168-179. PubMed ID: 32609666
[TBL] [Abstract][Full Text] [Related]
30. Genomic alterations in tumor tissue and ctDNA from Chinese pancreatic cancer patients.
Xiong A; Ma N; Wei G; Li C; Li K; Wang B
Am J Cancer Res; 2021; 11(9):4551-4567. PubMed ID: 34659905
[TBL] [Abstract][Full Text] [Related]
31. Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers.
Singhi AD; George B; Greenbowe JR; Chung J; Suh J; Maitra A; Klempner SJ; Hendifar A; Milind JM; Golan T; Brand RE; Zureikat AH; Roy S; Schrock AB; Miller VA; Ross JS; Ali SM; Bahary N
Gastroenterology; 2019 Jun; 156(8):2242-2253.e4. PubMed ID: 30836094
[TBL] [Abstract][Full Text] [Related]
32. Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma.
Philip PA; Azar I; Xiu J; Hall MJ; Hendifar AE; Lou E; Hwang JJ; Gong J; Feldman R; Ellis M; Stafford P; Spetzler D; Khushman MM; Sohal D; Lockhart AC; Weinberg BA; El-Deiry WS; Marshall J; Shields AF; Korn WM
Clin Cancer Res; 2022 Jun; 28(12):2704-2714. PubMed ID: 35302596
[TBL] [Abstract][Full Text] [Related]
33. Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer.
Sivapalan L; Thorn GJ; Gadaleta E; Kocher HM; Ross-Adams H; Chelala C
BMC Cancer; 2022 Apr; 22(1):369. PubMed ID: 35392854
[TBL] [Abstract][Full Text] [Related]
34. KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy.
Kullmann F; Hartmann A; Stöhr R; Messmann H; Dollinger MM; Trojan J; Fuchs M; Hollerbach S; Harder J; Troppmann M; Kutscheidt A; Endlicher E
Oncology; 2011; 81(1):3-8. PubMed ID: 21894049
[TBL] [Abstract][Full Text] [Related]
35. Germline DNA damage repair gene mutations in pancreatic cancer patients with personal/family histories of pancreas/breast/ovarian/prostate cancer in a Japanese population.
Hata T; Mizuma M; Motoi F; Ishida M; Ohtsuka H; Nakagawa K; Morikawa T; Furukawa T; Unno M
Ann Gastroenterol Surg; 2021 Nov; 5(6):853-864. PubMed ID: 34755017
[TBL] [Abstract][Full Text] [Related]
36. A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer.
Pishvaian MJ; Wang H; He AR; Hwang JJ; Smaglo BG; Kim SS; Weinberg BA; Weiner LM; Marshall JL; Brody JR
Clin Cancer Res; 2020 Oct; 26(19):5092-5101. PubMed ID: 32669374
[TBL] [Abstract][Full Text] [Related]
37. Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis.
Rebelatto TF; Falavigna M; Pozzari M; Spada F; Cella CA; Laffi A; Pellicori S; Fazio N
Cancer Treat Rev; 2019 Nov; 80():101895. PubMed ID: 31542591
[TBL] [Abstract][Full Text] [Related]
38. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
[TBL] [Abstract][Full Text] [Related]
39. Molecular characteristics of
Seeber A; Zimmer K; Kocher F; Puccini A; Xiu J; Nabhan C; Elliott A; Goldberg RM; Grothey A; Shields AF; Battaglin F; El-Deiry WS; Philip PA; Marshall JL; Hall M; Korn WM; Lenz HJ; Wolf D; Feistritzer C; Spizzo G
ESMO Open; 2020 Nov; 5(6):e000942. PubMed ID: 33229504
[TBL] [Abstract][Full Text] [Related]
40. Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in Taiwan.
Cheng SM; Su YY; Chiang NJ; Wang CJ; Chao YJ; Huang CJ; Tsai HJ; Chen SH; Chang CY; Tsai CR; Li YJ; Yen CJ; Chuang SC; Chang JS; Shan YS; Hwang DY; Chen LT
J Biomed Sci; 2024 Feb; 31(1):21. PubMed ID: 38350919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]